Fusion Biopsy is Estimated to Witness High Growth Owing to Advancements in Imaging Technologies

Author : Prachi CMI | Published On : 13 Jan 2025

The fusion biopsy market involves the integration of advanced imaging modalities such as magnetic resonance imaging (MRI), ultrasound and computed tomography (CT) with biopsy procedures to obtain targeted tissue samples. Fusion biopsy enables real-time visualization of the biopsy needle location through co-registration of pre-procedure and real-time images. This increases targeting accuracy and decreases the number of biopsy repetitions required, reducing discomfort for patients. Fusion biopsy has applications in diagnosis of cancer types including prostate, breast and lung cancer.

The Global Fusion Biopsy Market is estimated to be valued at US$ 791.1 Mn in 2025 and is expected to exhibit a CAGR of 8.7% over the forecast period 2025-2032.

Key Takeaways


Key players operating in the fusion biopsy market are GE Healthcare, Koninklijke Philips N.V., FUJIFILM Corporation, Siemens Healthineers, Hitachi, Ltd., Canon Medical Systems Corporation, Medtronic, Hologic, Inc., Varian Medical Systems, Boston Scientific Corporation, Becton, Dickinson and Company, Agilent Technologies, Inc., 3M Company, Carestream Health, and Neusoft Medical Systems Co., Ltd.


Fusion Biopsy Market Growth is involve growing adoption in breast biopsy procedures and expansion into developing regions. Technological advancements include software upgrades for improved co-registration accuracy, MRI-TRUS fusion platforms for prostate biopsies and development of robots to automate biopsy procedures.

Market Drivers
The high growth of the fusion biopsy market can be attributed to rising cancer incidence globally, increasing preference for minimally invasive procedures and technological advancements in imaging solutions. Integration of advanced imaging modalities with biopsy significantly improves targeting capabilities while reducing the need for repeated biopsies. This drives higher adoption across hospitals and diagnostic centers. Growing health awareness is also fueling early diagnosis through biopsy examinations.
 

Current Challenges in Fusion Biopsy Market
The adoption of fusion biopsy procedure is limited by its high costs. The high costs associated with the purchase and maintenance of imaging equipment required, such as MRI and TRUS machines, hinders the widespread adoption of fusion biopsy. Additionally, the fusion biopsy procedure demands advanced training for radiologists and interventional radiologists, which adds to its complexity. The fusion biopsy procedure is time-consuming as it requires coordination of imaging and needle guidance during the biopsy. Accuracy dependent on tissue deformations during real-time imaging and needle guidance is another challenge. Reimbursement policies pose challenges where payment rates do not always cover costs. Overcoming these challenges will help in expanding the patient access to fusion biopsy's benefits.

SWOT Analysis

Strength:
Precise target identification and real-time tracking allows accurate sampling of lesions. Increased cancer detection rate and ability to optimize biopsy strategy.
Weakness: High costs associated with expensive imaging equipment and need for specialized training. Procedure is time-consuming.
Opportunity: Increased adoption driven by superiority over traditional biopsy. Growing elderly population and rising cancer incidence create demand.
Threats: Alternatives like MRI-TRUS fusion gaining traction. Reimbursement policies remain a challenge.

Geographical regions with high market share in terms of value:

North America dominates the global fusion biopsy market owning to the major market share, backed by developed healthcare infrastructure, availability of advanced diagnostic technologies, and favorable reimbursement policies.

Fastest growing region:

Asia Pacific is poised to witness the highest growth during the forecast period. This is attributed to increasing awareness, improving healthcare infrastructure, rapidly growing elderly population which increases the risk of prostate cancer. Additionally, expanding health coverage across countries like India and China will propel the regional growth.

About Author:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)